BSX:NYSE

Boston Scientific (BSX) is trading at $71.9, well above the DCF‑derived fair value of $51.8 and its current PE of 37×, which exceeds the industry average of 25×, indicating the stock is **overvalued**. The price sits below its 20‑day, 50‑day and 200‑day SMAs (74.4, 85.2 and 97.3), and the computed trend is bearish, yet the RSI of 33 suggests the stock is *oversold* and the MACD histogram is positive, hinting at a possible short‑term bounce toward the $76.9 resistance. Support at $69.5 is holding, and volume remains stable, providing a modest liquidity cushion.
Fundamentally, BSX posted a 15.9% revenue growth year‑over‑year, strong gross (68.8%) and operating margins (19.7%), and generated $3.24 bn of free cash flow, supporting an aggressive $5 bn share‑repurchase authorization. Forward EPS of $3.92 translates to a forward PE of 18×, suggesting earnings upside. However, the company faces high regulatory risk from multiple class‑action lawsuits and a federal investigation tied to a stent recall, which could pressure sentiment and earnings in the near term.